
Global value dossiers are missing the access part of the story
With its focus on value, a traditional Global Value Dossier reinforces a common pitfall in clinical development and commercialisation. This is the idea that if
With its focus on value, a traditional Global Value Dossier reinforces a common pitfall in clinical development and commercialisation. This is the idea that if
Using epidemiological data, a patient-based forecasting model projected the gene therapy market outlook until 2036, evaluating global developments and their impact. Despite uncertainties, it emphasized the importance of preparedness and sustainability for public health resource stakeholders.
Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access.